1 / 13

Cardiac Diagnostics - Changing Practices Review of key markets in Europe

Sohail Sheikh Frost & Sullivan, 2003. Cardiac Diagnostics - Changing Practices Review of key markets in Europe. The Future of Cardiac Testing. Agenda Troponins in Europe - end user feedback Decentralised testing in cardiac diagnostics New and emerging markers Questions Motivation

jensen
Download Presentation

Cardiac Diagnostics - Changing Practices Review of key markets in Europe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sohail Sheikh Frost & Sullivan, 2003 Cardiac Diagnostics - Changing PracticesReview of key markets in Europe

  2. The Future of Cardiac Testing Agenda • Troponins in Europe - end user feedback • Decentralised testing in cardiac diagnostics • New and emerging markers • Questions Motivation • Troponin usage - how much, how often and how widespread ? • Demand for POCt - what factors effect uptake ? • Emerging markers - How widespread will their use be ?

  3. State of Cardiac Markers

  4. High Monthly usage per site Sw Fi Sp Fr It Dk % penetration of cTn in acute hosp. Ge 0 No 100 UK Ne Be Low Troponins Usage - 2002

  5. The Cost of Troponin

  6. Factors to Consider • COST IMPACT - POCt must have a real impact on cost savings through workflow patterns, ie. impacting on waiting times, hospitalisation and bed stay • TIME SENSITIVE - POCt which target conditions where a rapid result and response outweighs the high sensitivity/performance of lab tests. • PATIENT MANAGEMENT BENEFIT - A POCt allowing real benefits through therapeutic programmes, ie, the availability of routine medication following rapid diagnosis or by allowing constant monitoring of a patient drug regime, and or increase of QALY.

  7. What Markers Make Good POC Tests? PATIENT MANAGEMENT COST IMPACT GLUCOSE STREPA HP TROP TIME SENSITIVE

  8. Cardiac POCt - Challenges & Hurdles • Benefits of troponins still being fully realised • High up-front costs of POCt NOT offset by potential of cost savings • Lack of will amongst non-lab staff • Lack of end user choice

  9. TAM Ge Fr Sp It UK Scan Ne Be End user acceptance of cardiac POCt The Future of POC Testing

  10. End Users and New Markers • Lack of implementation practices - hindering usage • Low usage of BNPs not surprising • hs-CRP - widely researched, but less clinical applications so far • Only one visible company (Mercodia) offering mLDL

  11. Natriuretic Peptides - The New ‘Troponins’ ! • End users unable to differentiate between BNP and proBNP • Growth of proBNP will outpace BNP • 40% of NP market $ will be proBNP by 2005 • Adoption of NPs dictated by platform in use at lab • Over 50% of end users unable to quickly adopt BNP test

  12. And Finally…….. • Have companies forecasted the impact NP use will have on troponin sales? • If a troponin - NP double test panel is recommended, will there be end users jumping from one supplier to another? • What will happen to your supply chain if group purchasing continues?

  13. Thank You - Any Questions? For further information: call: +44 (0)20 7343 8383 email: enquiries@frost.com www.biotech.frost.com

More Related